JP2014503596A5 - - Google Patents

Download PDF

Info

Publication number
JP2014503596A5
JP2014503596A5 JP2013551380A JP2013551380A JP2014503596A5 JP 2014503596 A5 JP2014503596 A5 JP 2014503596A5 JP 2013551380 A JP2013551380 A JP 2013551380A JP 2013551380 A JP2013551380 A JP 2013551380A JP 2014503596 A5 JP2014503596 A5 JP 2014503596A5
Authority
JP
Japan
Prior art keywords
disorder
aminopyridine
therapeutic agent
agent according
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013551380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014503596A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/022960 external-priority patent/WO2012103471A1/en
Publication of JP2014503596A publication Critical patent/JP2014503596A/ja
Publication of JP2014503596A5 publication Critical patent/JP2014503596A5/ja
Withdrawn legal-status Critical Current

Links

JP2013551380A 2011-01-28 2012-01-27 脳性麻痺を治療するためのカリウムチャネル遮断薬の使用 Withdrawn JP2014503596A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161437558P 2011-01-28 2011-01-28
US61/437,558 2011-01-28
PCT/US2012/022960 WO2012103471A1 (en) 2011-01-28 2012-01-27 Use of potassium channel blockers to treat cerebral palsy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016132185A Division JP2016222685A (ja) 2011-01-28 2016-07-04 脳性麻痺を治療するためのカリウムチャネル遮断薬の使用

Publications (2)

Publication Number Publication Date
JP2014503596A JP2014503596A (ja) 2014-02-13
JP2014503596A5 true JP2014503596A5 (enExample) 2015-03-19

Family

ID=45567148

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013551380A Withdrawn JP2014503596A (ja) 2011-01-28 2012-01-27 脳性麻痺を治療するためのカリウムチャネル遮断薬の使用
JP2016132185A Pending JP2016222685A (ja) 2011-01-28 2016-07-04 脳性麻痺を治療するためのカリウムチャネル遮断薬の使用
JP2018136369A Pending JP2018197242A (ja) 2011-01-28 2018-07-20 脳性麻痺を治療するためのカリウムチャネル遮断薬の使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016132185A Pending JP2016222685A (ja) 2011-01-28 2016-07-04 脳性麻痺を治療するためのカリウムチャネル遮断薬の使用
JP2018136369A Pending JP2018197242A (ja) 2011-01-28 2018-07-20 脳性麻痺を治療するためのカリウムチャネル遮断薬の使用

Country Status (7)

Country Link
US (1) US20130030025A1 (enExample)
EP (2) EP2667869A1 (enExample)
JP (3) JP2014503596A (enExample)
AU (1) AU2012211101B2 (enExample)
BR (1) BR112013019265A2 (enExample)
CA (1) CA2825810A1 (enExample)
WO (1) WO2012103471A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
US9205577B2 (en) * 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
US11202853B2 (en) * 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
US10793893B2 (en) 2011-06-30 2020-10-06 Serb Sa Methods of administering 3,4-diaminopyridine
TWI592156B (zh) * 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
CA2909527A1 (en) * 2013-04-15 2014-10-23 Acorda Therapeutics, Inc. Methods for treating sensorimotor impairments associated with certain types of stroke using aminopyridines
WO2017168333A1 (en) * 2016-04-02 2017-10-05 Shilpa Medicare Limited Amifampridine dihydrochloride
WO2019126643A1 (en) * 2017-12-22 2019-06-27 Massachusetts Institute Of Technology Compositions and methods for williams syndrome (ws) therapy
WO2020163495A1 (en) * 2019-02-06 2020-08-13 Allergan, Inc. Combination therapy using clostridial toxin derivative and at least one chemical depolarizing agent
MD3989962T2 (ro) 2019-06-28 2025-12-31 Intrabio Ltd Gb Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală
WO2021144720A1 (en) 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers
JP2023520867A (ja) * 2020-04-08 2023-05-22 ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー 損傷後の顔面拘縮に対処するための治療戦略
KR20230015433A (ko) * 2020-05-22 2023-01-31 인트라바이오 리미티드 운동실조를 치료하기 위한 아세틸 류신과 4-아미노피리딘 또는 아세타졸아미드의 조합물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2085785C (en) * 1992-12-18 2005-03-15 Robert R. Hansebout The use of 4-aminopyridine in the treatment of a neurological condition
US5952357A (en) * 1993-12-23 1999-09-14 Cornell Research Foundation, Inc. Treating diseases of the anterior horn cells
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
WO2008030651A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
WO2008036294A2 (en) * 2006-09-19 2008-03-27 Northwestern University Nos inhibitors for treatment of motor deficit disorders
CA2691199C (en) * 2007-06-22 2017-09-12 Marc J. Simard Inhibitors of ncca-atp channels for therapy
US20120029035A1 (en) * 2009-02-11 2012-02-02 Acorda Therapeutics, Inc. Compositions and methods for extended therapy with aminopyridines
JO3348B1 (ar) * 2009-08-11 2019-03-13 Acorda Therapeutics Inc استخدام 4- بايريدين امينو لتحسين الادراك العصبي و/او التلف النفسي لدى مرضى يعانون من نقص النُخاعين وغير ذلك من امراض الجهاز العصبي

Similar Documents

Publication Publication Date Title
JP2005537268A5 (enExample)
CA2492081A1 (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
EA200800881A1 (ru) Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами
FI3668509T3 (fi) Menetelmä hoitaa amyotrofista lateraaliskleroosia pridopidiinilla
JP2019524856A5 (enExample)
JP2013507352A5 (enExample)
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
JP2001518509A5 (enExample)
JP2017506624A5 (enExample)
NZ569331A (en) COP 1 for treatment of inflammatory bowel diseases
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
ME02474B (me) Terapijski režimi
JP2013209384A5 (enExample)
JP2015522077A5 (enExample)
NO20080244L (no) Doseringsstyring for prasugrel
US20090149518A1 (en) Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis
JP2016505050A5 (enExample)
JP2014531470A5 (enExample)
TW201841635A (zh) 用於治療抑鬱症之組合物及方法
CN103977010B (zh) 一种犬用复方赛拉嗪注射剂及其制备方法
AU2019396829B2 (en) Adhesive pad
MX2014003997A (es) Metodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas.
JP2015509934A5 (enExample)
CAPAC The effect of LSD on the phantom limb phenomenon